Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Farnier

Showing results (51-60 of 144) with videos related to

Pageof 15
Sort By:
Archives of Cardiovascular Diseases|December 5, 2017
Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impactChristophe Bauters, Olivier Tricot, Gilles Lemesle, et al.
Presse Medicale (Paris, France : 1983)|September 2, 2019
[Myalgia and statins: Separating the true from the false]Jacques Blacher, Eric Bruckert, Michel Farnier, et al.
Journal of Comparative Effectiveness Research|March 9, 2023
Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based studyJean Ferrières, Eric Bruckert, Michel Farnier, et al.
European Journal of Preventive Cardiology|May 18, 2023
Effect of lipoprotein(a) levels on coronary lesion complexity in patients with acute myocardial infarction: data from the French RICO surveyIsabelle M Kouame, Michel Farnier, Frédéric Chague, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|February 6, 2021
PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarctionMarianne Zeller, Gilles Lambert, Michel Farnier, et al.
Journal of Clinical Lipidology|July 12, 2017
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 yearsMichel Farnier, Helen M Colhoun, William J Sasiela, et al.
Atherosclerosis|July 25, 2013
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemiaMichel Farnier, John R Guyton, Erin Jensen, et al.
Frontiers in Cardiovascular Medicine|March 30, 2026
Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINIJean Ferrières, Kausik K Ray, Alberico L Catapano, et al.
European Heart Journal|March 23, 2005
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemiaMichel Farnier, Mason W Freeman, Geraldine Macdonell, et al.
Journal of Personalized Medicine|June 24, 2022
Retinal Microvascular Changes in Familial Hypercholesterolemia: Analysis with Swept-Source Optical Coherence Tomography AngiographyPétra Eid, Louis Arnould, Pierre-Henry Gabrielle, et al.
Pageof 15

Showing results (51-60 of 144) with videos related to

Sort By:
Pageof 15
Archives of Cardiovascular Diseases|December 5, 2017
Reaching low-density lipoprotein cholesterol treatment targets in stable coronary artery disease: Determinants and prognostic impactChristophe Bauters, Olivier Tricot, Gilles Lemesle, et al.
Presse Medicale (Paris, France : 1983)|September 2, 2019
[Myalgia and statins: Separating the true from the false]Jacques Blacher, Eric Bruckert, Michel Farnier, et al.
Journal of Comparative Effectiveness Research|March 9, 2023
Evaluation of hypercholesterolemia management in at-risk patients by cardiologists in France: a case vignette-based studyJean Ferrières, Eric Bruckert, Michel Farnier, et al.
European Journal of Preventive Cardiology|May 18, 2023
Effect of lipoprotein(a) levels on coronary lesion complexity in patients with acute myocardial infarction: data from the French RICO surveyIsabelle M Kouame, Michel Farnier, Frédéric Chague, et al.
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|February 6, 2021
PCSK9 levels do not predict severity and recurrence of cardiovascular events in patients with acute myocardial infarctionMarianne Zeller, Gilles Lambert, Michel Farnier, et al.
Journal of Clinical Lipidology|July 12, 2017
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 yearsMichel Farnier, Helen M Colhoun, William J Sasiela, et al.
Atherosclerosis|July 25, 2013
Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemiaMichel Farnier, John R Guyton, Erin Jensen, et al.
Frontiers in Cardiovascular Medicine|March 30, 2026
Lipid management in high cardiovascular risk patients in France: a comparison with rest of Europe patients from 1-year follow-up of SANTORINIJean Ferrières, Kausik K Ray, Alberico L Catapano, et al.
European Heart Journal|March 23, 2005
Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemiaMichel Farnier, Mason W Freeman, Geraldine Macdonell, et al.
Journal of Personalized Medicine|June 24, 2022
Retinal Microvascular Changes in Familial Hypercholesterolemia: Analysis with Swept-Source Optical Coherence Tomography AngiographyPétra Eid, Louis Arnould, Pierre-Henry Gabrielle, et al.
Pageof 15